C57BL/6-Tnfrsf9tm1(TNFRSF9)Bcgen Erbb2tm1(ERBB2)Bcgen/Bcgen • 111869
| Product name | B-h4-1BB/hHER2 mice |
|---|---|
| Catalog number | 111869 |
| Strain name | C57BL/6-Tnfrsf9tm1(TNFRSF9)Bcgen Erbb2tm1(ERBB2)Bcgen/Bcgen |
| Strain background | C57BL/6 |
| NCBI gene ID | (Human) |
| Aliases | ILA; 4-1BB; CD137; CDw137; IMD109; NEU; NGL; HER2; TKR1; CD340; HER-2; VSCN2; MLN 19; MLN-19; c-ERB2; c-ERB-2; HER-2/neu; p185(erbB2) |
Strain specific analysis of 4-1BB (TNFRSF9) and HER2 (ERBB2) gene expression in wild-type mice and B-h4-1BB/hHER2 mice by RT-PCR. Mouse Tnfrsf9 mRNA was detectable only in spleen of wild-type mice (+/+). Human TNFRSF9 mRNA was detectable only in spleen of homozygous B-h4-1BB/hHER2 mice (H/H;H/H), but not in wild-type mice. Mouse Erbb2 mRNA was detectable only in liver of wild-type mice (+/+). Human ERBB2 mRNA was detectable only in liver of homozygous B-h4-1BB/hHER2 mice (H/H;H/H), but not in wild-type mice.
Antitumor activity of anti-human HER2 ADC (Trastuzumab analog-MMAE, in-house) in B-h4-1BB/hHER2 mice. (A) Anti-human HER2 ADC inhibited B-hHER2 MC38 plus tumor growth in B-h4-1BB/hHER2 mice. Murine colon cancer B-hHER2 MC38 plus cells were subcutaneously implanted into homozygous B-h4-1BB/hHER2 mice (female, 8-week-old, n=6). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were intravenously injected with anti-human HER2 ADC Trastuzumab analog-MMAE (in-house) indicated in panel. (B) Body weight changes during treatment. As shown in panel A, 10mg/kg anti-human HER2 ADC was efficacious in controlling tumor growth in B-h4-1BB/hHER2 mice, demonstrating that B-hHER2 MC38 plus provide a powerful preclinical model for in vivo evalsuation of anti-human HER2 ADC. Values are expressed as mean ± SEM.